Iris Atrophy
Loss of iris stromal and/or pigment epithelial tissue that may be essential (primary, progressive, idiopathic — the hallmark of ICE syndrome) or secondary to uveitis, glaucoma, ischaemia, trauma, or surgical intervention. Recognition and classification guide urgency of referral and long-term glaucoma surveillance.
Last updated: March 2026
Panel A — Anterior View: Essential vs Secondary Iris Atrophy
Panel B — Iris Cross-Section: Normal Stroma vs Atrophic Changes
Essential (ICE Syndrome)
Progressive moth-eaten holes, corectopia, PAS → glaucoma. Unilateral, young women. HSV-triggered endothelial transformation.
Post-Inflammatory
Follows uveitis (HZO, Fuchs HCI), ACG. Sector atrophy, sphincter tears, posterior synechiae. May be bilateral.
Post-Traumatic / Iatrogenic
Follows blunt trauma, surgical iridectomy, laser iridotomy. Localised defects at injury site. Stable once healed.
Panel A. Essential iris atrophy (left): full-thickness holes (A), corectopia (B), transillumination defects (C). Secondary atrophy (right): sector thinning (D), sphincter tears (E), ectropion uveae (F), posterior synechiae (G).
Panel B. Three-column iris cross-section comparing normal full-thickness stroma vs essential atrophy (ICE membrane, stretch/MMP holes, PPE loss) vs secondary atrophy (sector thinning, sphincter necrosis, inflammatory infiltrate).
Iris atrophy describes the partial or complete loss of iris stromal architecture and/or pigment epithelium. It is broadly divided into two categories: essential iris atrophy, which is the hallmark feature of Iridocorneal Endothelial (ICE) syndrome — a progressive, unilateral condition in young-to-middle-aged women caused by abnormal corneal endothelial proliferation — and secondary iris atrophy, which follows identifiable anterior segment insults including anterior uveitis, acute angle closure glaucoma, herpes zoster ophthalmicus, trauma, laser procedures, and iris melanoma treatment.
Essential iris atrophy is distinguished by its progressive and asymmetric pattern, frequently accompanied by corectopia (distorted pupil), peripheral anterior synechiae, and progressive glaucoma. Secondary atrophy, by contrast, tends to follow the distribution of the inciting pathology — sector atrophy from posterior uveitis, sphincter necrosis from ischaemic angle closure, or diffuse heterochromic atrophy in Fuchs heterochromic iridocyclitis. In both categories, slit-lamp biomicroscopy and transillumination are essential diagnostic tools, and glaucoma risk must be actively monitored throughout the patient's lifetime.
Essential Iris Atrophy (ICE Syndrome)
Caused by abnormal corneal endothelial cells that acquire epithelial-like behaviour and proliferate beyond their normal territory. These ICE cells migrate across the trabecular meshwork and onto the anterior iris surface, secreting matrix metalloproteinases (MMPs) that degrade the iris stroma. A contractile fibrovascular membrane then distorts and destroys the remaining iris tissue. Herpes simplex virus (HSV) has been proposed as the initiating trigger based on HSV DNA detection in corneal endothelial specimens from ICE syndrome patients.
Secondary Iris Atrophy
- Anterior uveitis: Inflammatory mediators (prostaglandins, cytokines), direct leukocytic infiltration, and enzymatic degradation destroy iris stroma and vasculature; posterior synechiae formation leads to sector and diffuse atrophy.
- Acute angle closure glaucoma (AACG): Ischaemic necrosis of the iris sphincter and anterior stroma from acute IOP elevation; results in fixed, mid-dilated pupil and sphincter tears (glaukomflecken on lens, not iris, but co-occurs).
- Herpes zoster ophthalmicus (HZO): VZV-induced vasculitis of iris vasculature with secondary ischaemia; produces sectoral transillumination defects that are characteristic and highly specific for VZV uveitis.
- Fuchs heterochromic iridocyclitis (FHI): Chronic low-grade uveitis causing diffuse iris stromal atrophy with heterochromia; iris vessels are fragile and bleed easily on gonioscopy (Amsler sign).
- Trauma: Direct iris sphincter tears from blunt force; iris dialysis; penetrating injury disrupting stromal architecture.
- Post-laser (argon laser iridotomy/iridoplasty): Focal thermal atrophy at laser application site; transillumination defects at LPI site.
- Iris melanoma radiotherapy: Proton beam or plaque brachytherapy for iris tumour causes localised atrophy in the treatment field.
Essential Iris Atrophy (ICE Syndrome Mechanism)
- Abnormal corneal endothelial cells (ICE cells) lose contact inhibition and proliferate beyond the corneal endothelial layer — possibly triggered by prior HSV infection causing endotheliitis and endothelial cell transformation.
- ICE cells migrate posteriorly across the trabecular meshwork, forming a thin fibrocellular membrane that progressively occludes the angle, creating peripheral anterior synechiae (PAS) and secondary angle-closure glaucoma.
- The membrane extends further onto the anterior iris surface, covering the iris stroma.
- ICE cells secrete matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, which degrade type IV collagen and laminin in the iris stroma, causing direct stromal dissolution.
- Contractile forces within the fibrovascular membrane pull the iris toward the corneal periphery, distorting the pupil (corectopia) in the direction of the membrane traction.
- Progressive membrane contraction stretches and perforates residual iris tissue, creating full-thickness holes characteristic of essential iris atrophy.
- The opposite direction of pupillary distortion corresponds to the sector of PAS and membrane traction — the pupil is pulled toward the area of heaviest membrane.
Secondary Iris Atrophy
- In inflammatory atrophy: activated macrophages, T-lymphocytes, and neutrophils infiltrate the iris stroma, releasing proteolytic enzymes that degrade stroma; posterior synechiae formation further compromises iris vascular supply.
- In ischaemic atrophy (AACG): acute IOP elevation compresses iris vasculature; ischaemic necrosis of the sphincter muscle and anterior iris stroma produces permanent structural damage within hours of pressure elevation.
- In HZO-related atrophy: VZV replicates in iris vascular endothelium, triggering vasculitis, occlusion of iris vessels, and patchy ischaemic infarction producing sectoral transillumination defects.
- End result in all secondary forms: loss of the normal cellular and vascular architecture of iris stroma, with replacement by fibrous scar tissue or simple absence of tissue.
| Category | Subtype | Key Features |
|---|---|---|
| Essential (ICE Spectrum) | Essential Iris Atrophy | Iris destruction predominates; corectopia, full-thickness iris holes, progressive atrophy |
| Chandler Syndrome | Corneal oedema predominates; iris changes mild; glaucoma with relatively low IOP | |
| Cogan-Reese Syndrome | Pedunculated iris nodules; stromal atrophy; ICE cell membrane surrounds nodules | |
| Secondary | Post-inflammatory | Sector or diffuse atrophy following uveitis; posterior synechiae common |
| Ischaemic | Sphincter necrosis from AACG; fixed dilated pupil; sphincter tears | |
| Viral (HZO/HSV) | Sectoral TIDs along VZV/HSV distribution; vasculitis mechanism | |
| Traumatic | Focal sphincter tears, iridodialysis; history of injury | |
| Iatrogenic | Focal atrophy at laser iridotomy/iridoplasty sites; post-radiotherapy field changes |
Essential Iris Atrophy / ICE Syndrome
- Female sex: Strong female predominance (approximately 3:1 female-to-male ratio)
- Age 30–50 years: Typical presentation in young-to-middle-aged adults; rarely presents in childhood
- Unilateral presentation: Bilateral cases exist but are exceedingly rare (<5%)
- Prior HSV infection: HSV seropositivity elevated in ICE patients; proposed as viral trigger for endothelial transformation
- White ethnicity: More commonly reported in white populations, though cases described across all ethnicities
Secondary Iris Atrophy
- History of acute angle closure glaucoma: Ischaemic sphincter necrosis during attack; risk proportional to duration and IOP elevation
- Anterior uveitis (any cause): Particularly recurrent or chronic uveitis; HLA-B27-associated and herpetic uveitis highest risk
- Herpes zoster ophthalmicus: VZV reactivation in the V1 dermatomal distribution; sectoral iris ischaemia is characteristic
- Blunt ocular trauma: Sphincter tears and iridodialysis from direct mechanical injury
- Prior laser iridotomy/iridoplasty: Focal thermal damage at treatment site
- Fuchs heterochromic iridocyclitis: Chronic subclinical inflammation causing progressive diffuse iris stromal thinning
- Prolonged elevated IOP: Chronic ischaemic compromise of iris vasculature
Slit-Lamp Biomicroscopy
- Transillumination defects (TIDs): Light passes through atrophic areas; moth-eaten or spoke-like pattern on retroillumination; full-thickness holes appear as well-demarcated red-reflex windows
- Stromal thinning: Loss of normal iris crypts and furrows; stroma appears thin and translucent; sphincter muscle may become visible
- Corectopia: Distorted or displaced pupil — pathognomonic of ICE syndrome essential atrophy variant; pupil is pulled toward the quadrant of heaviest membrane/PAS
- Full-thickness iris holes: Well-demarcated holes in iris tissue; characteristic of advanced essential atrophy; not seen in secondary atrophy
- Sphincter tears and notches: Irregular pupil margin with radial tears; following AACG or trauma; sphincter may be completely non-reactive
- Sector atrophy: Wedge-shaped region of thinned iris stroma; common following focal uveitis or HZO; distribution corresponds to area of ischaemia or inflammation
- Ectropion uveae: Posterior pigment epithelium visible on anterior iris surface at pupillary margin; indicates distortion of iris architecture; seen in ICE and severe uveitis
- Heterochromia: Diffuse iris atrophy in Fuchs HCI causes depigmentation of affected eye; lighter iris compared to fellow eye
- Beaten-silver corneal endothelium: Subtle finding in ICE variants; indicates underlying abnormal endothelial cell population
Gonioscopy
- Peripheral anterior synechiae (PAS): Progressive broad-based PAS in ICE; may extend to or beyond Schwalbe line; correlates with glaucoma severity
- Iris stromal atrophy visible at iris insertion (gonioscopically flat iris in ICE)
- Trabecular membrane/pigmentation in ICE from ICE cell migration
Specular Microscopy (ICE-Specific)
- ICE cells: reversed dark-light pattern (dark centres, light periphery — opposite to normal endothelium); irregular cell shapes; pleomorphism; loss of hexagonality
- Reduced endothelial cell density
- Often asymptomatic early: Essential iris atrophy in ICE may be noticed incidentally or by the patient noticing a change in pupil shape or iris appearance
- Blurred vision: Secondary to corneal oedema (Chandler variant) or elevated IOP reducing corneal clarity; morning blur that improves during the day is classic for corneal oedema from Chandler syndrome
- Halos around lights: Corneal oedema causing light scatter; also from elevated IOP
- Photophobia: Abnormal pupil shape and size (corectopia) alters light regulation; also from corneal surface irregularity
- Visual distortion: Significant corectopia displacing the visual axis may cause irregular astigmatism and monocular diplopia
- Ocular pain/pressure: Elevated IOP from progressive angle closure; may be chronic dull ache or acute if IOP spikes
- Cosmetic concern: Patient may notice asymmetric appearance of pupils or iris colour difference (heterochromia in Fuchs HCI)
- Reduced visual field: Late presentation of secondary glaucomatous optic neuropathy; often silent until advanced
Glaucoma
The most vision-threatening complication. Occurs in approximately 50% of ICE syndrome patients, driven by progressive PAS occluding the trabecular meshwork. Secondary glaucoma also develops after post-uveitis synechial angle closure and post-AACG trabecular damage. Glaucoma in ICE is particularly refractory to medical management due to progressive membrane formation, often requiring surgical intervention.
Corneal Oedema and Decompensation
In Chandler syndrome (ICE variant), the abnormal ICE cells are inadequate pumping cells, leading to progressive corneal endothelial failure. Stromal and epithelial oedema results in reduced vision, pain (from epithelial bullae), and ultimately requires corneal transplantation (DSAEK or DMEK) for visual rehabilitation.
Vision Loss
Results from untreated glaucoma (optic nerve damage), corneal decompensation (central corneal oedema), or secondary cataract formation from chronic topical medications or steroid use in uveitis.
Cosmetic and Functional Distress
Progressive corectopia and iris destruction cause visible disfigurement; patients may experience monocular diplopia or irregular image from eccentric visual axis placement. Cosmetic prosthetic lenses can help but carry their own risks in a compromised anterior segment.
- Herpes simplex virus (HSV) — ICE syndrome: Elevated HSV seropositivity in ICE patients; HSV DNA detected in corneal endothelial specimens; proposed as trigger for endothelial transformation. No active systemic HSV disease required — latent viral infection may be sufficient initiating stimulus
- Herpes zoster (VZV) — secondary atrophy: Dermatomal HZO (V1 trigeminal distribution) causes anterior uveitis with sectoral iris ischaemia; characteristic sectoral TIDs pathognomonic of VZV uveitis
- Ankylosing spondylitis / HLA-B27-associated diseases: Recurrent acute anterior uveitis leading to progressive posterior synechiae and sector iris atrophy; most common systemic cause of secondary iris atrophy from uveitis in young adults
- Sarcoidosis: Granulomatous anterior uveitis may cause mutton-fat KPs, broad posterior synechiae, and progressive iris stromal involvement
- Juvenile idiopathic arthritis (JIA): Chronic anterior uveitis in ANA-positive children; silent inflammation leads to band keratopathy, cataract, and iris atrophy from persistent low-grade inflammation
- Essential iris atrophy (ICE): No direct systemic disease associations beyond proposed HSV link; no malignant transformation; no internal organ involvement
- Slit-lamp biomicroscopy: Essential first step; document transillumination defects (retroillumination technique), corectopia, stromal thinning, ectropion uveae, presence/absence of anterior chamber cells and flare; corneal clarity and beaten-silver appearance
- Specular microscopy: Gold standard for ICE diagnosis; demonstrates characteristic ICE cells with reversed dark-light pattern, pleomorphism, and loss of hexagonality; abnormal findings extend beyond clinically visible disease
- Corneal confocal microscopy: Non-invasive in vivo imaging detects ICE cells at the sub-basal nerve plexus level; supports ICE diagnosis in early or subtle cases
- Gonioscopy: Mandatory for angle assessment; documents extent of PAS, trabecular meshwork pigmentation or membrane, angle grade; distinguishes open angle from synechial closure
- Anterior segment OCT (AS-OCT): High-resolution imaging of anterior chamber angle, peripheral iris configuration, and PAS; non-contact; useful for monitoring progression
- Ultrasound biomicroscopy (UBM): 50 MHz imaging of angle and ciliary body; visualises structures behind iris; confirms synechiae, angle depth, and rules out posterior segment pathology
- IOP monitoring: Essential at every visit; diurnal variation curves if IOP is borderline; corneal-corrected tonometry given potential corneal irregularity
- Optic nerve assessment and visual fields: HRT/OCT optic nerve head scan and Humphrey VF to detect and monitor glaucomatous damage; establishes baseline and monitors progression
- Fluorescein iris angiography: Documents iris vascular anatomy; used to confirm iris ischaemia in secondary atrophy, assess neovascularisation, or rule out vascular iris lesion
- HSV/VZV serology and aqueous PCR: For suspected viral-induced secondary atrophy (HZO uveitis, HSV iritis); aqueous PCR for HSV/VZV is more specific than serology in active uveitis
1. Address Underlying Cause (Secondary Atrophy)
Treatment of the primary pathology is essential to halt progression of secondary atrophy. For uveitis: topical corticosteroids (prednisolone acetate 1%), cycloplegics (cyclopentolate 1%, homatropine 2%) to prevent synechiae formation; systemic immunosuppression for chronic/recurrent disease. For AACG: immediate IOP-lowering (topical beta-blocker, alpha agonist, IV acetazolamide, mannitol), followed by laser peripheral iridotomy to prevent recurrence. For HZO: systemic antivirals (oral aciclovir 800 mg 5 times daily, or valaciclovir 1 g TDS × 7-10 days); topical steroids for anterior uveitis component.
2. Glaucoma Management (ICE / Secondary)
Medical therapy: topical hypotensives as first line — prostaglandin analogues (latanoprost, bimatoprost), beta-blockers (timolol), carbonic anhydrase inhibitors (dorzolamide, brinzolamide), alpha-2 agonists (brimonidine). In ICE syndrome, medical therapy is often insufficient long-term due to progressive PAS formation.
Surgical therapy: trabeculectomy with antimetabolite (MMC) for ICE-related glaucoma, but failure rates are higher than in POAG due to progressive membrane overgrowth of the bleb. Glaucoma drainage devices (Ahmed or Baerveldt tube shunts) are generally preferred for ICE glaucoma, providing more durable IOP control. Cyclophotocoagulation (CPC — transcleral or endoscopic) for refractory cases.
3. Corneal Decompensation (Chandler Syndrome)
Early corneal oedema: hypertonic saline drops (5% NaCl q.i.d.) and ointment (5% NaCl nocte) to draw fluid from corneal stroma osmotically; soft bandage contact lens for pain relief from epithelial bullae; hair dryer at arm's length to evaporate epithelial moisture in the morning. Advanced or visually significant oedema: Descemet stripping automated endothelial keratoplasty (DSAEK) or Descemet membrane endothelial keratoplasty (DMEK) for selective replacement of diseased endothelium; awareness that ICE cells may recur on the donor graft.
4. Antiviral Therapy for ICE (Experimental)
Oral aciclovir has been proposed to suppress the putative HSV trigger in ICE syndrome. Small case series suggest possible slowing of progression but no randomised controlled trial evidence exists. Generally not standard of care but may be considered in confirmed HSV-seropositive ICE patients under ophthalmology guidance.
5. Iris Atrophy Itself: No Reversible Treatment
No pharmacological or surgical treatment reverses established iris atrophy. Management is directed at preventing further damage (IOP control, uveitis suppression) and treating complications. Cosmetic coloured contact lenses or iris prosthetic implants may be considered by specialist surgeons for severe cosmetic disturbance from corectopia.
Singapore Optometry Scope Note: Optometrists should recognise iris transillumination defects and corectopia as urgent findings requiring specialist referral. If ICE syndrome is suspected (unilateral progressive iris changes, young-to-middle-aged woman), refer for specular microscopy. Monitor IOP at every visit for all patients with established iris atrophy, regardless of cause. Iris atrophy following anterior uveitis warrants increased vigilance for secondary glaucoma from synechial angle closure — baseline gonioscopy and optic nerve imaging is essential. Document any progressive corectopia with serial slit-lamp photography as a sign of ICE progression. Co-manage glaucoma medications under ophthalmology supervision. Do not initiate topical steroids empirically for unilateral iris changes without ruling out ICE syndrome.
- Secondary iris atrophy (controlled cause): Generally stable once the underlying condition is adequately treated; established iris atrophy does not regress but further progression halts with disease control
- Essential iris atrophy / ICE syndrome: Progressive and lifelong disorder with no known cure; rate of progression varies between individuals and between ICE subtypes
- Glaucoma in ICE: Increasingly difficult to control as the angle progressively closes; medical therapy alone is insufficient long-term in most patients; tube shunt surgery provides longer-term IOP control than trabeculectomy; visual prognosis depends on optic nerve damage at time of diagnosis
- Corneal decompensation (Chandler): DSAEK/DMEK is effective for visual rehabilitation; however, ICE cells may recur on the graft endothelium, necessitating repeat transplantation over the patient's lifetime
- Timing of diagnosis: Early diagnosis and IOP control before significant optic nerve damage is the single most important prognostic factor in ICE-related glaucoma
- Post-uveitis atrophy: Vision prognosis depends on degree of glaucoma, cataract, and macular complications rather than iris atrophy itself
| Condition | Key Differentiator |
|---|---|
| Fuchs endothelial corneal dystrophy | Bilateral; corneal guttata on specular microscopy; no iris atrophy or corectopia; no glaucoma from angle closure; older age of onset |
| Axenfeld-Rieger syndrome | Bilateral; congenital onset; posterior embryotoxon; iris strands to Schwalbe line; associated systemic anomalies (dental, skeletal); normal specular microscopy |
| Posterior polymorphous corneal dystrophy (PPCD) | Bilateral; autosomal dominant; hereditary; vesicular/band-like corneal lesions; milder iris changes; normal-appearing specular cells |
| Iridoschisis | Elderly patients; splitting (schisis) of iris stroma into layers; free-floating fibrils visible in anterior chamber; no endothelial disease; shallow anterior chamber |
| Fuchs heterochromic iridocyclitis | Unilateral; diffuse iris atrophy with heterochromia; small stellate KPs diffusely on endothelium; Amsler sign (iris bleed on gonioscopy); no corectopia or iris holes; associated with toxoplasma or rubella |
| Traumatic iris damage | History of blunt or penetrating trauma; sphincter tears at pupillary margin; iridodialysis; angle recession on gonioscopy; no ICE cells; no progressive PAS |
| Pigment dispersion syndrome | Radial mid-peripheral TIDs (not full-thickness holes); young myopic males; Krukenberg spindle; no corectopia; dense TM pigmentation on gonioscopy |
- Shields MB. Textbook of Glaucoma. 4th ed. Baltimore: Williams & Wilkins; 1998. Chapter on ICE syndrome and iris atrophy.
- Eagle RC Jr, Font RL, Yanoff M, Fine BS. Proliferative endotheliopathy with iris abnormalities: the iridocorneal endothelial syndrome. Arch Ophthalmol. 1979;97(11):2104–2111.
- Laganowski HC, Sherrard ES, Muir MG, Buckley RJ. Distinguishing features of the iridocorneal endothelial syndrome and posterior polymorphous dystrophy: value of endothelial specular microscopy. Br J Ophthalmol. 1991;75(4):212–216.
- Wilson ME. Congenital iris ectropion and a new classification for anterior segment dysgeneses. J Pediatr Ophthalmol Strabismus. 1990;27(1):48–55.
- Huna-Baron R, Barnett Mizrahi E, Shapiro A. Secondary glaucoma following iridocorneal endothelial syndrome. Ophthalmic Surg Lasers Imaging. 2010;41:S82–S86.
- Chandler PA. Atrophy of the stroma of the iris; endothelial dystrophy, corneal edema, and glaucoma. Am J Ophthalmol. 1956;41(4):607–615.
- Cogan DG, Reese AB. A syndrome of iris nodules, ectopic Descemet's membrane, and unilateral glaucoma. Doc Ophthalmol. 1969;26:424–433.
- Alvarado JA, Murphy CG, Juster RP, Hetherington J Jr. Pathogenesis of Chandler's syndrome, essential iris atrophy and the Cogan-Reese syndrome. Invest Ophthalmol Vis Sci. 1986;27(6):853–872.